Introducing the next generation of Decipher Prostate RP

Decipher's genomic test, performed on tumor tissue, helps match treatment timing and intensity with the metastatic potential of the tumor.

Our new three-page test report makes it easier to understand and discuss your patient's personalized genomic test results

Contact Us

Decipher Prostate RP delivers personalized data based on the patient's Decipher score, which ranges from zero to 1 and indicates whether the genomic characteristics of the tumor indicate low, intermediate, or high risk.

Page 1 contains the Decipher Score, risk estimates, and an interpretation of the score.

Page 1 image
1
Decipher Score
  • Determined by
    tumor biology alone, not influenced by clinicopathologic variables (e.g., Gleason, PSA)
  • 22 genes, 7 biological pathways
  • Continuous genomic risk score
  • 3 categories of risk (low, intermediate, high)
2
Risk Estimates
  • Based on the Decipher score

Metastasis

  • Risk within 5 & 10 years
  • Best surrogate endpoint for overall survival

Prostate Cancer Mortality

  • Risk within 15 years
3
Interpretation
  • Summary based on the patient’s genomic risk & relevant clinical findings

Page 2 contains case analysis, interpretation, clinical findings, and treatment graphics.

Page 2 image
4
Dynamic Report
  • The report is tailored to the clinical presentation of the patient
5
Interpretation
  • Explains risk comparison graphic
  • Specifies the percentile of risk for this patient
6
Risk Comparison
  • This patient’s 10-year risk of metastasis is compared to 987 patients with similar clinical features
  • For these patients, Decipher risk groups are distributed as:
    • 35% Low
    • 16% Intermediate
    • 49% High

Distribution of risk is dependent on clinical risk group

7
Treatment Graphics
  • Evidence from Decipher Prostate RP studies
  • Radiotherapy Timing (Left)
    • Risk of metastasis with
      post-RP radiotherapy
      is dependent on the Decipher score and PSA level at time of treatment
  • Treatment Intensity (Right)
    • Risk of progression to
      ADT after radiotherapy alone in conjunction with the Decipher score and PSA level can help with the hormone therapy decision
8
Clinical Findings
  • Clinical study results relevant to this patient

Page 3 contains a test description, intended use info, confidence intervals, references, and a QR code for more info.

Page 3 image
9
Test Description
  • How the test is performed
  • Definitions for each of the endpoints reported
  • Provides detail on the cut-points for Decipher risk groups
10
Intended Use
  • Decipher Prostate RP is intended for use in men with localized prostate cancer after surgery with undetectable, persistent, or rising PSA
11
Confidence Intervals
  • The 95% confidence interval for each endpoint reported
12
QR Code
  • Directs you to more information about each study
13
References
  • For each of the clinical studies cited in the report

Decipher offers clinicians a new and meaningful perspective by providing a calculation of a patient’s genomic risk that doesn’t factor in other clinical characteristics.

Decipher SM Icons